Tequin, one of the brand names for the pharmaceutical product Gatifloxacin, was introduced to the U.S. market by Bristol-Myers Squibb in 1999. The drug, an antibiotic, was prescribed primarily for the treatment of respiratory tract infections.
In 2006, a report in the New England Journal of Medicine alleged that Tequin had been found to put users at an elevated risk for dysglycemia, a blood sugar metabolism disorder that may manifest as either hyperglycemia (high blood sugar) or hypoglycemia (low blood sugar). Initially, Bristol-Myers Squibb notified health care providers that product warnings would be enhanced. However, the company subsequently opted to terminate the manufacture of Tequin. The product is now available only as treatment for eye conditions, in the form of an eye drop.
If you experienced side effects after being prescribed Tequin, GetLegal has the tools and resources to help you find skilled legal representation to protect your rights. Visit our attorney directory, look for your geographic location and find the best lawyer for your situation.
Defective Drugs & Medical Devices Topics
Happy 4th of July
Our country is not the only thing to which we owe our allegiance. It is also owed to justice and to…Read More 02 Jul 2020, Thursday
Supreme Court Issues Landmark LGBT Employment Law Ruling
Decision Applies Civil Rights Act to Employment Issues in All 50 States The United States Supreme Co…Read More 25 Jun 2020, Thursday
President Seeks to Limit Liability of Meat Companies for COVID-19
Industry Continues to Be Hotspot for COVID Infection State health officials in Idaho announced on Tu…Read More 09 Jun 2020, Tuesday